Outcome following high-dose methotrexate in pregnancies misdiagnosed as ectopic

Am J Obstet Gynecol. 2011 Dec;205(6):533.e1-3. doi: 10.1016/j.ajog.2011.07.002. Epub 2011 Jul 20.

Abstract

Objective: The objective of this study was to report the outcomes of intrauterine pregnancies misdiagnosed as ectopic and exposed to methotrexate, a major teratogen.

Study design: We report the outcomes of all subjects who sought consultation after exposure to high-dose methotrexate to induce abortion in presumed ectopic pregnancies, which were later identified as viable intrauterine pregnancies by 3 North American Teratology Information Services between 2002 and 2010.

Results: Eight women with normal, desired pregnancies were administered high-dose methotrexate in the first trimester because of presumed, misdiagnosed ectopic pregnancies. All pregnancies resulted in catastrophic outcomes. Two pregnancies resulted in severely malformed newborns with methotrexate embryopathy; 3 women miscarried shortly after exposure, and in 3 the erroneous diagnosis led the physicians to advise and perform surgical termination.

Conclusion: Erroneous diagnosis of intrauterine pregnancies as ectopic with subsequent first-trimester exposure to methotrexate may result in the birth of severely malformed babies or fetal demise.

MeSH terms

  • Abnormalities, Drug-Induced / etiology
  • Abortifacient Agents, Nonsteroidal / administration & dosage
  • Abortifacient Agents, Nonsteroidal / adverse effects*
  • Abortion, Spontaneous / chemically induced
  • Adult
  • Diagnostic Errors*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects*
  • Pregnancy
  • Pregnancy Outcome*
  • Pregnancy Trimester, First / drug effects
  • Pregnancy, Ectopic / diagnosis*
  • Pregnancy, Ectopic / drug therapy*
  • Teratogens
  • Treatment Outcome

Substances

  • Abortifacient Agents, Nonsteroidal
  • Teratogens
  • Methotrexate